Urinary Tract Infection Treatment Market by Disease Type and Geography - Forecast and Analysis 2021-2025

  • Published: Nov 2021
  • Pages: 120
  • SKU: IRTNTR46392
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The urinary tract infection (UTI) treatment market share is expected to increase by USD 2.66 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 4.71%.

This urinary tract infection treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by disease type (uncomplicated UTI and complicated UTI) and geography (North America, Europe, Asia, and ROW). The urinary tract infection treatment market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd. among others.

What will the Urinary Tract Infection Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Urinary Tract Infection (UTI) Treatment Market Size for the Forecast Period and Other Important Statistics

 

Urinary Tract Infection Treatment Market: Key Drivers and Trends

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The rising incidence rate of UTI is notably driving the UTI treatment market growth, although factors such as the development of antibacterial resistance may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the urinary tract infection treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Urinary Tract Infection Treatment Market Driver

One of the key factors driving growth in the urinary tract infection treatment market is the rising incidence rate of UTI. Interconnection of UTI with other healthcare conditions and changing lifestyle habits have led to the rising incidence of the disease. This, in turn, is expected to raise the demand for treatment facilities for UTI. The disease is more common in women as compared with men. Around 50% of the women globally have chances of developing UTI at least once in their lifetime. This accounts for a large population and demands huge attention. Apart from gender, many other factors, such as obesity and diabetes, contribute to the rising incidence of UTI.

Key Urinary Tract Infection Treatment Market Challenge

The development of antibacterial resistance will be a major challenge for the urinary tract infection treatment market. UTI is primarily a bacterial infection. The development of antibacterial resistance organisms is a huge challenge for the global UTI treatment market. MDR microorganisms make UTIs more severe. MDR microorganisms are the species of organisms that exhibit resistance to several antimicrobial drugs. MDR bacteria are considered the most threatening group among all these organisms as they have shown a significant impact on public health. The MDR microorganisms, such as MDR E. coli, have been found to be a major infecting organism, especially in healthcare settings, and are a major point of concern for healthcare providers.

This urinary tract infection treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Urinary Tract Infection Treatment Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.

 

This statistical study of the urinary tract infection treatment market encompasses successful business strategies deployed by the key vendors. The UTI treatment market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The urinary tract infection treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Urinary Tract Infection Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

35% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for urinary tract infection treatment in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The availability of a large number of companies has led to easy access to the treatment. This will facilitate the urinary tract infection treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Type Segments in the Urinary Tract Infection Treatment Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The urinary tract infection treatment market share growth by the uncomplicated UTI segment will be significant during the forecast period. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the UTI treatment market size and actionable market insights on post COVID-19 impact on each segment.

 

Urinary Tract Infection Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 4.71%

Market growth 2021-2025

$ 2.66 billion

Market structure

Fragmented

YoY growth (%)

3.97

Regional analysis

North America, Europe, Asia, and ROW

Performing market contributiIon

North America at 35%

Key consumer countries

US, Canada, Germany, China, and UK

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Urinary Tract Infection Treatment Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive urinary tract infection treatment market growth during the next five years
  • Precise estimation of the urinary tract infection treatment market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the UTI treatment industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of UTI treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025

    Five Forces Analysis

    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Disease type

    • Market segments
    • Comparison by Disease type
    • Uncomplicated UTI - Market size and forecast 2020-2025
    • Complicated UTI - Market size and forecast 2020-2025
    • Market opportunity by Disease type

    Customer landscape

      Geographic Landscape

      • Geographic segmentation
      • Geographic comparison
      • North America - Market size and forecast 2020-2025
      • Europe - Market size and forecast 2020-2025
      • Asia - Market size and forecast 2020-2025
      • ROW - Market size and forecast 2020-2025
      • Key leading countries
      • Market opportunity by geography
      • Market drivers
      • Market challenges
      • Market trends

      Vendor Landscape

      • Overview
      • Landscape disruption

      Vendor Analysis

      • Vendors covered
      • Market positioning of vendors
      • Abbott Laboratories
      • AbbVie Inc.
      • AstraZeneca Plc
      • Boehringer Ingelheim International GmbH
      • Cipla Inc.
      • F. Hoffmann-La Roche Ltd.
      • GlaxoSmithKline Plc
      • Merck and Co. Inc.
      • Pfizer Inc.
      • SHIONOGI Co. Ltd.

      Appendix

      • Scope of the report
      • Currency conversion rates for US$
      • Research methodology
      • List of abbreviations

      Research Framework

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      TechnavioINFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases
      Technavio

      TechnavioDATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts
      Technavio

      TechnavioREPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape
      Interested in this report?
      Get your FREE sample now!
      The urinary tract infection (uti) treatment market growth will increase by $2668.80 million during 2020-2025.
      The urinary tract infection (uti) treatment market is expected to grow at a CAGR of 4.71% during 2020-2025.
      Technavio has segmented the urinary tract infection (uti) treatment market by other1 (Uncomplicated UTI and Complicated UTI) and geographic (North America, Europe, Asia, and ROW).
      Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., SHIONOGI Co. Ltd. are a few of the key vendors in the urinary tract infection (uti) treatment market.
      North America will register the highest growth rate of 34.66% among the other regions. Therefore, the urinary tract infection (uti) treatment market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
      The key factors driving the urinary tract infection (uti) treatment market growth are:
      • Relation of UTI with several other factors leading to rising incidence rate of UTI
      • Growing awareness of controlled usage of antibiotics
      The urinary tract infection (uti) treatment market vendors should focus on grabbing business opportunities from the uncomplicated uti segment as it accounted for the largest market share in the base year.
      Safe and Secure SSL Encrypted
      Technavio

      Single User:

      2500 USD

      Technavio Get the report (PDF) sent to your email within minutes.

      Subscribe & Save

      Get lifetime access to our
      Technavio Insights

      Want to customize this report?

      This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

      We offer $1000 worth of FREE customization at the time of purchase
      Technavio
      Enquire Before Buying
      1. Home
      2. Health Care
      3. Published Report
      17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>